BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity

Yiyi Chu; Ying Yuan

doi:10.1111/rssc.12255

journal article Jan 14, 2018

BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity

Journal of the Royal Statistical Society Series C: Applied Statistics Vol. 67 No. 3 pp. 723-740 · Oxford University Press (OUP)

View at Publisher Save 10.1111/rssc.12255

Abstract

SummaryThe basket trial refers to a new type of phase II cancer trial that evaluates the therapeutic effect of a targeted agent simultaneously in patients with different types of cancer that involve the same genetic or molecular aberration. Although patients who are enrolled in the basket trial have the same molecular aberration, it is common for the targeted agent to be effective for patients with some types of cancer, but not others. We propose a Bayesian latent subgroup trial (BLAST) design to accommodate such treatment heterogeneity across cancer types. We assume that a cancer type may belong to the sensitive subgroup, which is responsive to the treatment, or the insensitive subgroup, which is not responsive to the treatment. Conditionally on the latent subgroup membership of the cancer type, we jointly model the binary treatment response and the longitudinal biomarker measurement that represents the biological activity of the targeted agent. The BLAST design makes the interim go–no-go treatment decision in a group sequential fashion for each cancer type on the basis of accumulating data. The simulation study shows that the BLAST design outperforms existing trial designs. It yields high power to detect the treatment effect for sensitive cancer types that are responsive to the treatment and maintains a reasonable type I error rate for insensitive cancer types that are not responsive to the treatment.

Topics

No keywords indexed for this article. Browse by subject →

References

28

[1]

Berry "The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research" Molec. Oncol. (2015) 10.1016/j.molonc.2015.02.011

[2]

Berry "Bayesian hierarchical modeling of patient subpopulations: efficient designs of phase II oncology clinical trials" Clin. Trials (2013) 10.1177/1740774513497539

[3]

Chu (2017)

[4]

Cunanan "An efficient basket trial design" Statist. Med. (2017) 10.1002/sim.7227

[5]

Flexible smoothing with B-splines and penalties

Paul H. C. Eilers, Brian D. Marx

Statistical Science 1996 10.1214/ss/1038425655

[6]

Fan (1996)

[7]

Fitzmaurice (2008) 10.1201/9781420011579

[8]

Flaherty "Inhibition of mutated, activated BRAF in metastatic melanoma" New Engl. J. Med. (2010) 10.1056/nejmoa1002011

[9]

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

Gini F. Fleming, Michael W. Sill, Kathleen M. Darcy et al.

Gynecologic Oncology 2010 10.1016/j.ygyno.2009.09.025

[10]

Freidlin "Borrowing information across subgroups in phase II trials: is it useful?" Clin. Cancer Res. (2013) 10.1158/1078-0432.ccr-12-1223

[11]

Galon "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome" Science (2006) 10.1126/science.1129139

[12]

Gatzemeier "Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer" Ann. Oncol. (2004) 10.1093/annonc/mdh031

[13]

Stochastic Relaxation, Gibbs Distributions, and the Bayesian Restoration of Images

Stuart Geman, Donald Geman

IEEE Transactions on Pattern Analysis and Machine... 1984 10.1109/tpami.1984.4767596

[14]

Reversible jump Markov chain Monte Carlo computation and Bayesian model determination

PETER J. GREEN

Biometrika 1995 10.1093/biomet/82.4.711

[15]

Green (1993) 10.1201/b15710

[16]

Li "Bayesian inference in semiparametric mixed models for longitudinal data" Biometrics (2010) 10.1111/j.1541-0420.2009.01227.x

[17]

Okada "Pathways of apoptotic and non-apoptotic death in tumour cells" Nat. Rev. Cancer (2004) 10.1038/nrc1412

[18]

Pardoll "The blockade of immune checkpoints in cancer immunotherapy" Nat. Rev. Cancer (2012) 10.1038/nrc3239

[19]

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Anirudh Prahallad, Chong Sun, Sidong Huang et al.

Nature 2012 10.1038/nature10868

[20]

Redig "Basket trials and the evolution of clinical trial design in an era of genomic medicine" J. Clin. Oncol. (2015) 10.1200/jco.2014.59.8433

[21]

Ruppert (2003) 10.1017/cbo9780511755453

[22]

Simon "Implementing personalized cancer genomics in clinical trials" Nat. Rev. Drug Discvry (2013) 10.1038/nrd3979

[23]

Spiegelhalter "Bayesian measures of model complexity and fit (with discussion)" J. R. Statist. Soc. B (2002) 10.1111/1467-9868.00353

[24]

Thall "Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes" Statist. Med. (1995) 10.1002/sim.4780140404

[25]

Thall "Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes" Statist. Med. (2003) 10.1002/sim.1399

[26]

Tiacci "BRAF mutations in hairy-cell leukemia" New Engl. J. Med. (2011) 10.1056/nejmoa1014209

[27]

Yuan (2016)

[28]

Zuiverloon "Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review" Eur. Urol. (2012) 10.1016/j.eururo.2011.09.026

Cited By

55

An adaptive biomarker basket design in phase II oncology trials

Shufang Liu, Kentaro Takeda · 2022

Pharmaceutical Statistics

Design and analysis of umbrella trials: Where do we stand?

Luke O. Ouma, James M. S. Wason · 2022

Frontiers in Medicine

Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers

Kentaro Takeda, Shufang Liu · 2021

Statistics in Medicine

Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials

Liyun Jiang, Lei Nie · 2021

Contemporary Clinical Trials

Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework

Peter Murphy, David Glynn · 2021

Health Technology Assessment

Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials

Guosheng Yin, Zhao Yang · 2020

Statistics in Biopharmaceutical Res...

Metrics

55

Citations

28

References

Details

Published: Jan 14, 2018
Vol/Issue: 67(3)
Pages: 723-740
License: View

Authors

Y

Yiyi Chu

University of Texas School of Public Health , Houston , USA

Y

Ying Yuan

University of Texas MD Anderson Cancer Center Houston , USA

Cite This Article

Yiyi Chu, Ying Yuan (2018). BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity. Journal of the Royal Statistical Society Series C: Applied Statistics, 67(3), 723-740. https://doi.org/10.1111/rssc.12255

BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity

You May Also Like